The fact that VH20 targeting TCE and CARs eradicates both cell lines indicates that VH20 targeting ALK seems independent of ALK mutation status, which might be superior to traditional TKIs and can be applicable to a broad population of cancer patients. Here, ALK is linked to cancer.